4.6 Article

Photoinduced Covalent Irreversible Inactivation of Proline Dehydrogenase by S-Heterocycles

期刊

ACS CHEMICAL BIOLOGY
卷 16, 期 11, 页码 2268-2279

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acschembio.1c00427

关键词

-

资金

  1. Advanced Light Source, a DOE Office of Science User Facility [DE-AC02-05CH11231]
  2. ALS-ENABLE program - National Institutes of Health, National Institute of General Medical Sciences [P30 GM124169-01]
  3. National Institute of General Medical Sciences from the National Institutes of Health [P30 GM124165]
  4. DOE Office of Science by Argonne National Laboratory [DE-AC02-06CH11357]

向作者/读者索取更多资源

The discovery of a new class of PRODH inactivator that covalently and irreversibly modifies the FAD in a light-dependent manner provides a new approach for developing photopharmacological drugs targeting cancer cells. The inactivation process involves exposure to bright white light, leading to irreversible loss of enzyme activity and potential photosensitivity of cancer cells.
Proline dehydrogenase (PRODH) is a flavoenzyme that catalyzes the first step of proline catabolism, the oxidation of L -proline to Delta 1-pyrroline-5-carboxylate. PRODH has emerged as a cancer therapy target because of its involvement in the metabolic reprogramming of cancer cells. Here, we report the discovery of a new class of PRODH inactivator, which covalently and irreversibly modifies the FAD in a light-dependent manner. Two examples, 1,3-dithiolane-2-carboxylate and tetrahydrothiophene-2-carboxylate, have been characterized using X-ray crystallography (1.52-1.85 A resolution), absorbance spectroscopy, and enzyme kinetics. The structures reveal that in the dark, these compounds function as classical reversible, proline analogue inhibitors. However, exposure of enzyme-inhibitor cocrystals to bright white light induces decarboxylation of the inhibitor and covalent attachment of the residual S-heterocycle to the FAD N5 atom, locking the cofactor into a reduced, inactive state. Spectroscopic measurements of the inactivation process in solution confirm the requirement for light and show that blue light is preferred. Enzyme activity assays show that the rate of inactivation is enhanced by light and that the inactivation is irreversible. We also demonstrate the photosensitivity of cancer cells to one of these compounds. A possible mechanism is proposed involving photoexcitation of the FAD, while the inhibitor is noncovalently bound in the active site, followed by electron transfer, decarboxylation, and radical combination steps. Our results could lead to the development of photopharmacological drugs targeting PRODH.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据